INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Beebe Katherine		2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTNP]				
(Last)	(First)	(Middle)	02/19/2019 4. Relationship of Reporting Person(s) to Issuer			ç	5. If Amendment, Date Original Filed(Month/Day/Year)
400 OYSTEI	R POINT B	SLVD.,					1
SUITE 505			(Check a	all applicable)			
(Street) SOUTH SAN FRANCISCO, CA 94080				Director 10% Owner X_ Officer Other (give title below) (specify below) Chief Scientific Officer		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City)	(State)	(Zip)	Tabla I -	Non-Dorivot	tivo Socuriti	oc Ro	neficially Owned
1.Title of Secur (Instr. 4)	ity		2. Amount o Beneficially (Instr. 4)	of Securities	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		ture of Indirect Beneficial ership
Common Sto	ock		2,387		D	Â	
Reminder: Repo owned directly o		te line for ea	ch class of securities benefic	cially S	SEC 1473 (7-02)	
	inform	ation conta	oond to the collection of ained in this form are no nd unless the form disp	t			

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		(1130.4)	Derivative	Security:	
		Title		5	
			Security	Direct (D)	

Edgar Filing: Beebe Katherine - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Option (Right to Buy)	(1)	(1)	Common Stock	28,487	\$ 1.56	D	Â
Option (Right to Buy)	(2)	03/16/2025	Common Stock	4,243	\$ 19.8	D	Â
Option (Right to Buy)	(3)	03/07/2028	Common Stock	28,335	\$ 5.82	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Beebe Katherine 400 OYSTER POINT BLVD., SUITE 505 SOUTH SAN FRANCISCO, CA 94080	Â	Â	Chief Scientific Officer	Â	

Signatures

/s/Katherine Beebe DeVarney	02/25/2019		
<u>**</u> Signature of Reporting Person	Date		

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents currently vested options that were granted between May 2009 and February 2017 that were repriced effective January 23,
 (1) 2019. Of such options, 7,576 expire on May 17, 2019, with the balance expiring on various dates between May 11, 2021 and February 13, 2027.
- (2) These options, which were granted in March 2015, are fully vested.
- (3) These options, which were granted in March 2017, are fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.